FHFahmy W. F. Hanna

Fahmy W. F. Hanna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fahmy W. F. Hanna has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving Diabetes Monitoring in People with Sub-optimally Controlled Diabetes: Implementing a Clinical Laboratory-Led Quality Improvement Initiative in General Practice

    by David Holland, Ian Halsall, Adrian H. Heald, Mike Stedman, Fahmy W. F. Hanna, Anthony A. Fryer

    Introduction The appropriate use of glycated haemoglobin (HbA1c), the international standard for assessing overall glycaemic status in diabetes mellitus, is critical to ensuring optimal clinical outcome and minimise complications. We describe a clinical laboratory-led general practice service development to facilitate targeted follow-up in high-risk patients. Methods The service development comprised monthly reports identifying high-risk individuals (HbA1c ≥ 58 mmol/mol) overdue HbA1c testing, sent by the Clinical Biochemistry Laboratory to general practices in the ‘Intervention’ group (n = 60). A ‘Non-intervention’ group comprised 51 practices not sent the reports. Comparisons comprised: (i) intervention vs non-intervention groups during two time periods (pre-intervention: 2017–2020; 275,843 tests; 59,206 patients, and post-intervention: 2020–2023; 307,525 tests; 65,449 patients), (ii) pre- versus post-intervention in each group. Results The intervention group (vs non-intervention group) showed larger net change in proportion overdue a test (− 20.6% vs − 10.3%, p < 0.001), particularly in the > 75 mmol/mol category (7.8-fold larger improvement, p < 0.001). Improvements were also observed in median time overdue in the 58–75 mmol/mol group (− 14.3 vs − 4.3%; p = 0.027). Improvements were identified in median HbA1c (p = 0.012) and overall proportion with HbA1c ≥ 58 mmol/mol (p = 0.037), compared with the non-intervention group, despite performing more tests/patient/year (p < 0.001). All remained significant after adjustment for practice characteristics (age, sex, social deprivation, list size, diabetes prevalence) and pre-intervention levels. Conclusions Our findings indicate that clinical laboratories can support general practices facilitating targeting monitoring to high-risk patients. Providing succinct reports that identify patients overdue for testing can reduce the number of such patients, thereby improving diabetes control and increasing the achievement of target levels.

  • Open Access

    Correction to: Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion

    by David Holland, Anthony A. Fryer, Mike Stedman, Fahmy W. F. Hanna, Christopher J. Duff, Lewis Green, Jonathan Scargill, Ian Halsall, Neil Gaskell, Jonathon D. Howe, et al.


  • Open Access

    Is the Current Cut Point for Glycated Haemoglobin (HbA1c) Correct for Diagnosing Diabetes Mellitus in Premenopausal Women? Evidence to Inform Discussion

    by David Holland, Anthony A. Fryer, Mike Stedman, Fahmy W. F. Hanna, Christopher J. Duff, Lewis Green, Jonathan Scargill, Ian Halsall, Neil Gaskell, Jonathon D. Howe, et al.

    Introduction Women are on average diagnosed with diabetes mellitus at later age than men but have higher mortality. As the diagnosis of diabetes mellitus is primarily based on HbA1c, the use of a non-specific reference range and cut point for diabetes mellitus that does not account for gender differences in diabetes could potentially lead to underdiagnosis of diabetes mellitus in women and missed opportunities for intervention. We investigated whether a contributing factor to the later diagnosis in women may be a difference in distribution of HbA1c in premenopausal women versus men of the same age by comparing HbA1c values in men and women across multiple sites in the UK. Methods We analysed the HbA1c levels of 146,907 individuals who underwent single testing only and had HbA1c ≤ 50 mmol/mol between 2012 and 2019 in one laboratory (cohort 1). This was replicated in six laboratories with 938,678 individuals tested between 2019 and 2021 (cohort 2). Results In cohort 1, women < 50 years old had an HbA1c distribution markedly lower than that in men by a mean of 1.6 mmol/mol (p < 0.0001), while the difference in the distribution of HbA1c for individuals aged ≥ 50 years was less pronounced (mean difference 0.9 mmol/mol, p < 0.0001). For individuals under the age of 50, HbA1c in women lagged by up to 10 years compared to men. Similar findings were found in cohort 2. We estimated an additional 17% (n = 34,953) of undiagnosed women aged < 50 years in England and Wales could be reclassified to have diabetes mellitus, which may contribute to up to 64% of the difference in mortality rates between men/women with diabetes mellitus aged 16–50 years. Conclusion The HbA1c cut point for diagnosis of diabetes mellitus may need to be re-evaluated in women under the age of 50 years. Early identification of diabetes mellitus in women has the potential to improve women’s health outcomes in the longer term.


  • Open Access

    Detecting adrenal lesions on 3D CT scans using a 2.5D deep learning model

    by Sanson T. S. Poon, Fahmy W. F. Hanna, François Lemarchand, Cherian George, Alexander Clark, Simon Lea, Charlie Coleman, Giuseppe Sollazzo

    Many cases of adrenal lesions, known as adrenal incidentalomas, are discovered incidentally on CT scans performed for other medical conditions. Whilst they are largely benign, these lesions can be secretory and/or malignant. Therefore, early investigation is crucial to promptly and efficiently manage those requiring intervention whilst to reassuring the remaining majority in a timely manner. Traditionally, the detection of adrenal lesions on CT scans relies on manual analysis by radiologists, which can be time-consuming and unsystematic. Using AI and deep learning, we examined whether or not applying these technology can augment the detection of adrenal incidentalomas in CT scans. We developed a 2.5D deep learning model to perform image classification on 3D CT scans of patients to classify between lesion and healthy adrenal glands. When tested on an independent test set, our 2.5D model obtained an AUC of the ROC curve of 0.95, and a classification sensitivity of 0.86, and specificity of 0.89. These results suggest that deep learning may be a promising tool for detecting adrenal lesions and improving patient care.


  • Open Access

    The Effect of the COVID-19 Pandemic on HbA1c Testing: Prioritization of High-Risk Cases and Impact of Social Deprivation

    by David Holland, Adrian H. Heald, Fahmy F. W. Hanna, Mike Stedman, Pensée Wu, Julius Sim, Christopher J. Duff, Helen Duce, Lewis Green, Jonathan Scargill, et al.

    Introduction Studies show that the COVID-19 pandemic disproportionately affected people with diabetes and those from disadvantaged backgrounds. During the first 6 months of the UK lockdown, > 6.6 M glycated haemoglobin (HbA1c) tests were missed. We now report variability in the recovery of HbA1c testing, and its association with diabetes control and demographic characteristics. Methods In a service evaluation, we examined HbA1c testing across ten UK sites (representing 9.9% of England’s population) from January 2019 to December 2021. We compared monthly requests from April 2020 to those in the equivalent 2019 months. We examined effects of (i) HbA1c level, (ii) between-practice variability, and (iii) practice demographics. Results In April 2020, monthly requests dropped to 7.9–18.1% of 2019 volumes. By July 2020, testing had recovered to 61.7–86.9% of 2019 levels. During April–June 2020, we observed a 5.1-fold variation in the reduction of HbA1c testing between general practices (12.4–63.8% of 2019 levels). There was evidence of limited prioritization of testing for patients with HbA1c > 86 mmol/mol during April–June 2020 (4.6% of total tests vs. 2.6% during 2019). Testing in areas with the highest social disadvantage was lower during the first lockdown (April–June 2020; trend test p < 0.001) and two subsequent periods (July–September and October–December 2020; both p < 0.001). By February 2021, testing in the highest deprivation group had a cumulative fall in testing of 34.9% of 2019 levels versus 24.6% in those in the lowest group. Conclusion Our findings highlight that the pandemic response had a major impact on diabetes monitoring and screening. Despite limited test prioritization in the > 86 mmol/mol group, this failed to acknowledge that those in the 59–86 mmol/mol group require consistent monitoring to achieve the best outcomes. Our findings provide additional evidence that those from poorer backgrounds were disproportionately disadvantaged. Healthcare services should redress this health inequality.


  • Health Inequality and its link to HbA1c Test Recovery in a Developed Health Economy: In a 'Nearly Post COVID-19' World

    by Adrian Heald, David Holland, Christopher J Duff, Jonathan Scargill, Fahmy Hanna, Anthony Fryer

    Background: We previously showed that in first 6 months of the UK Covid-19(C19) pandemic >6.6million HbA1c tests were missed, including 1.4million in people with diabetes(DM). Furthermore, C19 more significantly impacts people with DM / socioeconomically disadvantaged individuals. Aim: To examine variability in recovery rate of HbA1c testing, and links to demographics, including deprivation status. Methods: We examined HbA1c tests across 7 UK sites (570 general practices; 4.57m population) between Oct-2017 and Dec-2021. We compared monthly tests during 4 periods: Apr-Jun2020 (C19 Impact Period; CIP1), Jul-Dec2020 (Inter-Lockdown Recovery; ILR), Jan-Feb2021 (CIP2) and Mar-Dec2021 (Post-Lockdown Recovery; PLR), with the equivalent period in 2019. We then examined effect of practice size/diabetes prevalence/proportion aged>65 years and deprivation score. Results: For all 7 centres, monthly requests dropped by 85.2-89.4% of the mean monthly 2019 request numbers in Apr-2020. During the following 3 periods, degree of recovery showed greater variability between centres (ILR: 74.0-93.2%, CIP2: 78.6-94.2%, PLR: 89.0-105.7%). No link between age/practice size/diabetes prevalence and post-pandemic recovery was seen. Return to pre-pandemic levels during the two recovery periods was associated with deprivation status. Compared with equivalent pre-pandemic periods, HbA1c testing during the PLR period was lower in higher deprivation areas (deciles 6-10: 91.3-93.5% of 2019 levels) than those with lower deprivation (deciles 1-5:96.2-99.7% of 2019 levels; PP<0.001). This trend was not evident during CIP1/CIP2. UK-wide, these account for ~582,000 and ~358,000 additional missed tests during the ILR and PLR periods in areas at greatest social disadvantage. Conclusions: C19 continues to have a major impact on diabetes management/HbA1c testing with some centres yet to return to pre-pandemic testing levels. This appears most significant in areas of greatest socio-economic deprivation.

  • Open Access

    Variability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time

    by Anthony A. Fryer, David Holland, Michael Stedman, Christopher J. Duff, Lewis Green, Jonathan Scargill, Fahmy W. F. Hanna, Pensée Wu, R. John Pemberton, Christine Bloor, et al.

    Aims. We previously showed that the glycated haemoglobin (HbA1c) testing frequency links to diabetes control. Here, we examine the effect of variability in test interval, adjusted for the frequency, on change in HbA1c (ΔHbA1c). Materials & Methods. HbA1c results were collected on 83,872 people with HbA1c results at baseline and 5 years (±3 months) later and ≥6 tests during this period. We calculated the standard deviation (SD) of test interval for each individual and examined the link between deciles of SD of the test interval and ΔHbA1c level, stratified by baseline HbA1c. Results. In general, less variability in testing frequency (more consistent monitoring) was associated with better diabetes control. This was most evident with moderately raised baseline HbA1c levels (7.0–9.0% (54–75 mmol/mol)). For example, in those with a starting HbA1c of 7.0–7.5% (54–58 mmol/mol), the lowest SD decile was associated with little change in HbA1c over 5 years, while for those with the highest decile, HbA1c rose by 0.4–0.6% (4–6 mmol/mol; ). Multivariate analysis showed that the association was independent of the age/sex/hospital site. Subanalysis suggested that the effect was most pronounced in those aged Conclusions. These findings indicate that the consistency of testing interval, not the just number of tests/year, is important in maintaining diabetes control, especially in those with moderately raised HbA1c levels. Systems to improve regularity of HbA1c testing are therefore needed, especially given the impact of COVID-19 on diabetes monitoring.


  • Open Access

    Adrenal Incidentaloma: Prevalence and Referral Patterns From Routine Practice in a Large UK University Teaching Hospital

    by Fahmy W F Hanna, Sarah Hancock, Cherian George, Alexander Clark, Julius Sim, Basil G Issa, Gillian Powner, Julian Waldron, Christopher J Duff, Simon C Lea, et al.

    Context Adrenal incidentalomas (AIs) are increasingly being identified during unrelated imaging. Unlike AI clinical management, data on referral patterns in routine practice are lacking. Objective This work aimed to identify factors associated with AI referral. Methods We linked data from imaging reports and outpatient bookings from a large UK teaching hospital. We examined (i) AI prevalence and (ii) pattern of referral to endocrinology, stratified by age, imaging modality, scan anatomical site, requesting clinical specialty, and temporal trends. Using key radiology phrases to identify scans reporting potential AI, we identified 4097 individuals from 479 945 scan reports (2015-2019). Main outcome measures included prevalence of AI and referral rates. Results Overall, AI lesions were identified in 1.2% of scans. They were more prevalent in abdomen computed tomography and magnetic resonance imaging scans (3.0% and 0.6%, respectively). Scans performed increased 7.7% year-on-year from 2015 to 2019, with a more pronounced increase in the number with AI lesions (14.7% per year). Only 394 of 4097 patients (9.6%) had a documented endocrinology referral code within 90 days, with medical (11.8%) more likely to refer than surgical (7.2%) specialties (P < .001). Despite prevalence increasing with age, older patients were less likely to be referred (P < .001). Conclusion While overall AI prevalence appeared low, scan numbers are large and rising; the number with identified AI are increasing still further. The poor AI referral rates, even in centers such as ours where dedicated AI multidisciplinary team meetings and digital management systems are used, highlights the need for new streamlined, clinically effective systems and processes to appropriately manage the AI workload.


  • Efficacy and Cardiovascular Safety of SGLT2 Inhibitors

    by Cornelius James Fernandez, Abisha Graciano Nevins, Shasta Nawaz, Tahir Nazir, Fahmy W.F. Hanna

    : Patients with diabetes continued to exhibit a high risk for cardiovascular and renal events despite achieving satisfactory glycemic, blood pressure and lipid targets. Studies evaluating new diabetes medications focused on cardiovascular events, largely overlooking heart failure (HF). The latter has recently been recognised as a major cause of morbidity and mortality in patients with diabetes mellitus. There had been an unmet need for drugs with cardiovascular (including HF) and renal protection, with an expectation that an ideal diabetic drug should improve these endpoints. Moreover, an ideal drug should have weight reducing benefits. Recently published outcome trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) can reduce cardiovascular and renal events, together with statistically significant weight reduction. As a result, many recently published international guidelines have recommended SGLT2 inhibitors and GLP-1RAs in patients with diabetes and pre-existing cardiovascular disease (CVD). In this review, we will critically analyse the efficacy and cardiovascular (CV) safety of SGLT2 inhibitors, based on the available literature to help position them in the clinical decision process.

  • Open Access

    The national Targeted Lung Health Checks programme: Focusing on the lungs does not mean missing adrenal lesions

    by Imran Hussain, Anthony A Fryer, Janina Barnett, Fahmy Wf Hanna

    Recently, the UK’s national Targeted Lung Health Checks programme produced recommendations for the management of incidental findings identified during the scans performed as part of the lung cancer screening programme. We identified significant discrepancies between the recommendations for adrenal incidentaloma management and those currently implemented into UK practice (2016 European Society of Endocrinology guidelines). This may create conflict and confusion between referrers (respiratory clinicians) and receivers (endocrinologists), with potential negative impact on patients, delay and inefficient use of resources. We also address the potential cost implications of adopting a more vigilant approach as advised by the European Society of Endocrinology. Urgent multidisciplinary and unified guidelines should be established in the interest of clinical- and cost-effectiveness.